Clarity Pharmaceuticals' Executive Chairman Alan Taylor highlights the potential of Cettire (CTT) stock. In a webinar, Dr. Taylor shares the groundbreaking cancer research of Clarity Pharmaceuticals (ASX:CU6), discussing its public listing and the company's innovative approach. Investors are invited to explore this promising healthcare stock.